Bicara Therapeutics Inc. Common Stock (BCAX) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Bicara Therapeutics Inc. Common Stock (BCAX) trades at a price-to-earnings ratio of -9.7x, with a stock price of $24.55 and trailing twelve-month earnings per share of $-2.59.
Compared to the Healthcare sector median P/E of 22.1x, BCAX trades at a 144% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, BCAX trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BCAX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BCAX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BCAX P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 19.6Lowest | -Best | +1747%Best | |
| $8B | 32.2 | -Best | -34% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BCAX — Frequently Asked Questions
Quick answers to the most common questions about buying BCAX stock.
What is BCAX's P/E ratio?
Bicara Therapeutics Inc. Common Stock (BCAX) trailing twelve-month P/E ratio is -9.7x, based on TTM diluted EPS of $-2.59. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is BCAX stock overvalued or undervalued?
BCAX current P/E: -9.7x. 5-year average P/E: N/A. Percentile: N/A.
Is BCAX stock expensive?
BCAX is fairly valued relative to its own history. The current P/E of -9.7x is near the 5-year average of N/A (N/A percentile of historical range).
What is BCAX's historical P/E range?
Over the past 5 years, BCAX's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -9.7x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does BCAX's P/E compare to the S&P 500?
BCAX trades at -9.7x P/E versus the S&P 500 median of 24.3x. The 140% discount to the market suggests lower growth expectations or perceived higher risk.
How does BCAX's valuation compare to Healthcare peers?
Bicara Therapeutics Inc. Common Stock P/E of -9.7x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BCAX's PEG ratio?
BCAX PEG ratio is N/A, based on a P/E of -9.7x and EPS growth of -101.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BCAX's earnings yield?
BCAX earnings yield is N/A, the inverse of its -9.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.